TY  - JOUR
TI  - Personalization of contemporary incretin therapy for obesity: a focused systematic review
AU  - I.R. Fakhradiyev
AU  - T.R. Fazylov
AU  - A.M. Kondybaeva
AU  - A.T. Musaev
AU  - N.K. Shaktay
AU  - Zh.B. Tileules
JO  - Global Medical Reviews
PY  - 2026
DA  - 2026-07-27
VL  - 1
IS  - 1
SP  - e0002
KW  - obesity
KW  - GLP-1
KW  - tirzepatide
KW  - semaglutide
KW  - personalized medicine
KW  - PRISMA 2020
KW  - HFpEF
KW  - OSA
KW  - MASH
AB  - Background: Contemporary incretin-based therapy has shifted obesity management from ranking drugs by mean weight loss alone toward selection based on dominant comorbidity, treatment persistence, route preference, tolerability, body composition, and the consequences of withdrawal. Objective: To synthesize evidence supporting phenotype-oriented selection of semaglutide, tirzepatide, oral incretin strategies, and triple GIP, GLP-1, and glucagon agonism in adults with obesity or overweight and clinically relevant comorbidity. Methods: A focused systematic review was conducted according to PRISMA 2020. MEDLINE, Embase, Scopus, Web of Science Core Collection, and CENTRAL were searched for evidence published from 1 January 2024 to 8 July 2026. Two reviewers independently screened records, extracted data, and assessed risk of bias. Results: Twenty-eight studies or contextual documents were included. Tirzepatide showed the strongest direct comparative weight-loss signal; semaglutide had mature cardiovascular and phase 3 hepatic evidence. Both agents had randomized evidence in obesity-related HFpEF. Conclusion: Phenotype-oriented selection is better supported than a single hierarchy based on weight loss. Route, cost, tolerability, persistence, reproductive plans, and muscle function should be incorporated into treatment planning.
UR  - https://glr.sciences.kz/article/personalization-of-contemporary-incretin-therapy
L2  - https://glr.sciences.kz/downloads/GMR_2026_1_1_e0002_personalization-of-contemporary-incretin-therapy.pdf
ER  -